- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Small HER2 Positive Breast Cancer: When is Enough? ; volume:39 ; number:01 ; year:2018 ; pages:1-3
Indian journal of medical & paediatric oncology ; 39, Heft 01 (2018), 1-3
- Contributor
-
Singh, Randeep
Gupta, Sudeep
- DOI
-
10.4103/ijmpo.ijmpo_12_17
- URN
-
urn:nbn:de:101:1-2021082610202496143740
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Singh, Randeep
- Gupta, Sudeep
Other Objects (12)
Targeted therapy for HER2 positive breast cancer
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
When ‘Enough and as Good’ is Not Good Enough
When Discrimination is Not Enough
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Targeted therapy for HER2 positive breast cancer
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
When ‘Enough and as Good’ is Not Good Enough
When Discrimination is Not Enough
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Targeted therapy for HER2 positive breast cancer
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
When ‘Enough and as Good’ is Not Good Enough
When Discrimination is Not Enough
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer